Trogenix

Reporter’s Notebook: The Overdue Breakout for Gene Therapy and Gene Editing In the wake of years of excitement and disappointment, genetic medicine innovators gather at the 2025 Meeting on the Mesa with a renewed sense of cautious optimism and responsibility. Don't miss Jonathan D. Grinstein, PhD's reporting from the Cell and Gene Meeting on the Mesa in Phoenix. Vertex Pharmaceuticals Ken Macnamara, Trogenix Allan Reine, Prime Medicine, Inc. Fyodor Urnov, University of California, Berkeley Tom Wilton, Rebecca Ahrens-Nicklas, Kiran Musunuru, Children's Hospital of Philadelphia, University of Pennsylvania Maria Kefalas,The Calliope Joy Foundation Devyn Smith, Arbor Biotechnologies Sadik Kassim, Danaher Corporation St. Jude Children's Research Hospital - ALSAC, Boston Children's Hospital, Seattle Children's #PrecisionMedicine #GeneTherapy #GeneEditing #CRISPR

Our CEO Ken Macnamara was a panellist at Alliance for Regenerative Medicine’s (ARM) CEO & Investor Summit on Sunday, alongside Kinnari Patel, PharmD, MBA, ARM Executive Committee member and panel Chair, Allan Reine, M.D., CEO, Prime Medicine, Joanne Smith-Farrell, CEO Be Bio, and Miquel Vila-Perello, Co-Founder & CEO, SpliceBio. The CEO & Investor Summit kicked off ARM’s Cell and Gene Meeting on the Mesa 2025 conference where Ken gave a company presentation showcasing Trogenix' 'Trojan Horse' approach to cancer treatment, our breakthrough Odysseus SSE platform, and highlighted our recent Series A financing round.     It was great to discuss our breakthrough approach to cancer therapy and connect with so many industry leaders at the event. Read our Series A financing press release here: https://lnkd.in/ewBXvb45

Following the announcement of our Series A financing this morning, Consultant Clinical Oncologist and Honorary Senior Clinical Lecturer Dr Faye Robertson, who will be the chief investigator of our upcoming Phase I/II clinical trial in Edinburgh, spoke with Rick Edwards on BBC Radio 5 Live Breakfast to discuss plans to advance our clinical development programme for aggressive cancers including glioblastoma. Listen to the segment on BBC Radio 5 in the following link starting at minute 15:00: https://lnkd.in/eZVEGbSP #Trogenix #Fundraise #Oncology #Innovation #Biotech #glioblastoma

This week, our CSO Steve Pollard will be in Spain attending the European Society of Gene and Cell Therapy (ESGCT) 2025. If you are attending, please reach out and connect with Steve to discuss Trogenix’s 'Trojan Horse' approach to cancer treatment, our breakthrough Odysseus SSE platform, and our recent Series A financing round. Read the full programme here: https://lnkd.in/drQrDA8z #ESGCT #Trogenix #Fundraise #Oncology #Innovation #Biotech

Following the announcement of our Series A financing this morning, Consultant Clinical Oncologist and Honorary Senior Clinical Lecturer Dr Faye Robertson, who will be the chief investigator of our upcoming Phase I/II clinical trial in Edinburgh, spoke with Rick Edwards on BBC Radio 5 Live Breakfast to discuss plans to advance our clinical development programme for aggressive cancers including glioblastoma. Listen to the segment on BBC Radio 5 in the following link starting at minute 15:00: https://lnkd.in/eZVEGbSP #Trogenix #Fundraise #Oncology #Innovation #Biotech #glioblastoma

We’re excited to announce that Trogenix has secured £70M ($95M) in a Series A financing round led by IQ Capital, with participation from founding investor 4BIO Capital, returning investors Cancer Research Horizons, The Brain Tumor Investment Fund, and new investors including Eli Lilly and Company, Meltwind Advisory LLP, LongeVC, and Calculus Capital. This funding will progress our clinical development of potentially curative therapies for aggressive cancers and support the advancement of our revolutionary Odysseus® platform! As part of this financing, Cancer Research Horizons has made its largest investment to date, validating the curative potential of Trogenix's breakthrough precision genetic medicines. We are grateful for the support of our investors and partners as we continue to pioneer a new era of cancer therapies. Read the full press release here: https://lnkd.in/ewBXvb45 #Trogenix #Fundraise #Oncology #Innovation #Biotech National Brain Tumor Society

Excited to share that Trogenix will be attending the Cell & Gene Meeting on the Mesa on 6-8 October in Phoenix, AZ organised by the Alliance for Regenerative Medicine. Our CEO Ken Macnamara will be giving a company presentation on 7 October at 9:45-10:00am MST showcasing our 'Trojan Horse' approach to cancer treatment and our breakthrough Odysseus SSE platform.   We look forward to discussing our breakthrough approach to cancer therapy. If you are attending and would like to connect, please reach out. #Trogenix #MeetingOnTheMesa

Next week, Trogenix will be at the HSBC Innovation Banking Day on 2 October 2025 in London! Our CEO Ken Macnamara will be showcasing our 'Trojan Horse' approach to cancer treatment and breakthrough Odysseus SSE platform followed by a Q&A session at the event. This exclusive event brings together leading oncology founders, pharma executives, and VCs to explore critical partnerships and funding opportunities in today's market. We'll be joining an impressive lineup of senior executives from global pharma and other biotech companies. #HSBCInnovationDay #Trogenix #Oncology #Biotech #Conference #Innovation

Next week, Trogenix will be at the HSBC Innovation Banking Day on 2 October 2025 in London! Our CEO Ken Macnamara will be showcasing our 'Trojan Horse' approach to cancer treatment and breakthrough Odysseus SSE platform followed by a Q&A session at the event. This exclusive event brings together leading oncology founders, pharma executives, and VCs to explore critical partnerships and funding opportunities in today's market. We'll be joining an impressive lineup of senior executives from global pharma and other biotech companies. #HSBCInnovationDay #Trogenix #Oncology #Biotech #Conference #Innovation